New diabetes clinical trial: A Research Study to See How Much CagriSema (1.0 mg Once Weekly) Lowers Blood Sugar and Body Weight Compared to Tirzepatide (5 mg Once Weekly) in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Published on: August 01, 2024 at 11:00PM
Conditions: Diabetes Mellitus, Type 2
Interventions: Drug: Cagrilintide; Drug: Semaglutide; Drug: Tirzepatide
Sponsors: Novo Nordisk A/S
Not yet recruiting
https://ift.tt/yA7USMx